TY - JOUR
T1 - Medical therapy for ulcerative colitis
AU - Jani, Niraj
AU - Regueiro, Miguel D.
PY - 2002
Y1 - 2002
N2 - Although newer therapeutic agents are being developed for the treatment of inflammatory bowel disease, aminosalicylates and corticosteroids remain the mainstay of treatment for UC (Tables 2-5). Patients who do not respond to these agents or become steroid dependent require immunomodulatory therapy or curative surgery. Cyclosporine represents the greatest treatment advance for UC in 10 years. The role of nicotine, heparin, antibiotics, probiotics, and SCFA in the treatment of UC is less clear, but these agents may offer an alternative therapeutic approach for patients intolerant or nonresponsive to standard therapy.
AB - Although newer therapeutic agents are being developed for the treatment of inflammatory bowel disease, aminosalicylates and corticosteroids remain the mainstay of treatment for UC (Tables 2-5). Patients who do not respond to these agents or become steroid dependent require immunomodulatory therapy or curative surgery. Cyclosporine represents the greatest treatment advance for UC in 10 years. The role of nicotine, heparin, antibiotics, probiotics, and SCFA in the treatment of UC is less clear, but these agents may offer an alternative therapeutic approach for patients intolerant or nonresponsive to standard therapy.
UR - http://www.scopus.com/inward/record.url?scp=0035986138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035986138&partnerID=8YFLogxK
U2 - 10.1016/S0889-8553(01)00010-3
DO - 10.1016/S0889-8553(01)00010-3
M3 - Article
C2 - 12122729
AN - SCOPUS:0035986138
SN - 0889-8553
VL - 31
SP - 147
EP - 166
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 1
ER -